Groupama Asset Managment Has $4.53 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Groupama Asset Managment decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 14.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,480 shares of the medical research company's stock after selling 3,054 shares during the quarter. Groupama Asset Managment's holdings in Amgen were worth $4,533,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the 3rd quarter worth about $29,000. Centricity Wealth Management LLC acquired a new position in Amgen in the fourth quarter valued at about $25,000. Synergy Investment Management LLC bought a new stake in Amgen during the fourth quarter worth about $34,000. Atala Financial Inc acquired a new stake in shares of Amgen during the fourth quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $36,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Down 5.0 %

AMGN stock traded down $15.46 during midday trading on Friday, hitting $294.39. 5,252,789 shares of the company's stock were exchanged, compared to its average volume of 2,726,356. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The company has a market cap of $158.15 billion, a PE ratio of 38.99, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The stock's fifty day moving average price is $304.18 and its 200-day moving average price is $297.24.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.23%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is presently 126.09%.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. This represents a 40.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on AMGN. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Citigroup restated a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Piper Sandler lifted their price target on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Bank of America raised their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Finally, UBS Group reaffirmed a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $314.04.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.